Betty Kim, MD, PhD, FRCSC, FAANS

Department of Neurosurgery, Division of Surgery

Meet Yon Son Betty Kim, M.D., Ph.D.

In the News

Study opens new avenue for immunotherapy drug development

Scientists develop novel mRNA delivery method using extracellular vesicles

Physician-scientist: I found my sense of belonging at MD Anderson

2021 class of Andrew Sabin Family Fellows: Francesca Cole, Ph.D.; Michael Curran, Ph.D.; Yejing Ge, Ph.D.; Vivek Subbiah, M.D.; Ching-Wei Tzeng, M.D.; Sangeeta Goswami, M.D., Ph.D.; Betty Y.S. Kim, M.D., Ph.D.; Pavlos Msaouel, M.D., Ph.D.; Michelle Hildebrandt, Ph.D.; Ethan Ludmir, M.D.

MD Anderson announces 2021 class of Andrew Sabin Family Fellows

Nanomedicine: Small particles with huge possibilities for cancer care

Present Title & Affiliation

Primary Appointment

Core Member and Scientist, James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Neurosurgery, Baylor College of Medicine, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Professor, Neurosurgery, Baylor College of Medicine, Houston, TX

Research Interests

As a Physician Scientist, Dr. Kim’s laboratory takes a multidisciplinary approach to the research of solid tumors with a specific focus on malignant primary and metastatic brain tumors. Her work has been published in journals such as the New England Journal of Medicine, Nature, Nature Nanotechnology, Nature Biomedical Engineering, Nature Reviews Immunology and Nature Reviews Drug Discovery. Dr. Kim’s lab is interested in understanding the molecular cross-talk that occurs between tumor and stromal cells within the tumor immune-microenvironment, while also developing multiple patented therapeutic strategies to inhibit tumorigenesis. Her current research primarily focuses on finding new ways to promote immune recognition of glioma cells to boost the efficacies of cancer immunotherapies. Her group also pursues the identification of predictive and prognostic biomarkers for personalized medicine in the context of brain tumors.

Education & Training

Degree-Granting Education

2008	University of Toronto, Toronto, CA, Biomaterials and Biomedical Engineering, PhD
2002	McMaster University, Hamilton, CA, Medicine, MD
1998	Oxford University, Oxfordshire, GB, Post-Colonial Literature, Visiting Scholar
1998	McGill University, Montreal, CA, Anatomy and Cell Biology, BSc (Hon)

Postgraduate Training

2012-2013	Clinical Fellowship, Skull Base Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas
2011-2012	CIP, Clinical Investigator, Royal College of Surgeons
2011-2012	FRCSC, Neurologic Surgeons, Royal College of Surgeons
2011-2012	Clinical Fellowship, Neurosurgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
2006-2011	Clinician Investigator Program, Neurologic Surgery, University of Toronto, Toronto
2005-2011	Clinical Residency and Ph.D, Neurosurgery, Surgeon Scientist Program, University of Toronto, Toronto
2002-2005	Clinical Residency, Neurosurgery, University of Ottawa, Ottawa
2000-2001	Research Fellowship, Neurologic Surgery, Brigham and Women’s Hospital, Boston, Massachusetts
2000-2000	Medical Research Scholar, Neurology and Oncology, Kennedy Krieger Institute, Baltimore, Maryland

Licenses & Certifications

2025	American Association for Physician Leadership (AAPL)
2019	Texas Medical Board
2012	Neurosurgery, Royal College of Physicians and Surgeons, Canada

Experience & Service

Faculty Academic Appointments

Associate Professor, Neurosurgery, Baylor College of Medicine, Houston, TX, 2019 - 2022

Associate Professor, Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2022

Associate Professor, Neurosurgery, Mayo Clinic, Jacksonville, FL, 2017 - 2019

Assistant Professor, Cancer Biology, Mayo Clinic, Jacksonville, FL, 2014 - 2019

Assistant Professor, Neuroscience, Mayo Clinic, Jacksonville, FL, 2014 - 2019

Assistant Professor, Neurosurgery, Mayo Clinic, Jacksonville, FL, 2013 - 2017

Administrative Appointments/Responsibilities

Vice Chair, Promotion & Tenure Committee-Research (PTC-R), The University of Texas MD Anderson Cancer Center, Houston, Texas, 2026 - Present

Chair, Radiation Oncology Chair Search Committee, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2026 - 2027

Vice Chair, Cancer Nanomedicine, Gordon Research Conference, 2025 - Present

Co-Chair, GBM TeamLab Science, Break Through Cancer, Boston, MA, 2024 - Present

Chair, Ascending Senior Faculty Committee, Chief Academic Office (CAO), The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - 2024

Member, GBM Extended Leadership Committee, Break Through Cancer, Boston, MA, 2021 - 2026

Co-Director, Brain SPORE Animal Core, University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2024

Director, Neurosurgical Research, Mayo Clinic Florida, Jacksonville, Florida, 2015 - 2019

Other Professional Positions

Co-Founder, Thavka Inc, Boston, MA, 2026 - Present

Member, Clinical Investigator Award Committee, Damon Runyon, Damon Runyon Cancer Research Foundation, New York, New York, 2026 - Present

Co-Founder, Livrance Inc, Houston, TX, 2026 - Present

Co-Founder, Laurette Bio, Houston, TX, 2025 - Present

Member, Scientific Advisory Council, American Brain Tumor Association, 2024 - Present

Co-Chair, Basic Science Special Interest Track, Brain Tumor, Society of Neuro-Oncology (SNO), 2023 - Present

Co-Lead, Radiosurgery Oversight Committee, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present

Principal Investigator, MD Anderson GBM Clinical Trial Team, Break Through Cancer, Boston, MA, 2023 - Present

Member, Brain Cancers Forum, White House Cancer Moonshot Program, Washington, DC, 2023 - 2024

Advisory Member, Image Guided Cancer Therapy Research Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - 2025

Member, Scientific Advisory Board, BrainUp, Chicago, IL, 2022 - 2025

Co-Leader, GBM Extended Team, Break Through Cancer, Boston, MA, 2021 - 2025

Co-Director, Skull Base Endoscopy Course, Mayo Clinic Cancer Center (Florida), Jacksonville, Florida, 2015 - 2019

Co-Director, Brain Tumor Biobank, Mayo Clinic Florida, Jacksonville, Florida, 2015 - 2019

Course Director, Clearpoint Neuroblation Course, Mayo Clinic Florida, Jacksonville, Florida, 2015 - 2018

Intramural Institutional Committee Activities

Participant, FACD Academy Program, The University of Texas MD Anderson Cancer Center, 2025 - Present

Member, Advance Best Practices Taskforce, The University of Texas MD Anderson Cancer Center, 2025 - 2026

Extramural Institutional Committee Activities

Member, Immunotherapy Platform Executive Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

Co-Chair, Allison Institute Internal Advisory Council (AIAC), The University of Texas MD Anderson Cancer Center, 2025 - Present

Faculty Mentor, IGCT T32 Training Program, The University of Texas MD Anderson Cancer Center, 2025 - Present

Member, Texas Business Women's Award Nominating Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

Member, Promotion and Tenure Committee-Research, The University of Texas MD Anderson Cancer Center, 2025 - Present

Reviewer, AIMBE International Drug Delivery, Biosensors and Nanotechnology Review Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

Member, Technology Task Force Committee (Capital Equipment), The University of Texas MD Anderson Cancer Center, 2024 - 2026

Member, Emerging Leader Workshop Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

Chair, Ascending Senior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2024 - 2025

Member, Search Committee, Chairman of Plastic Surgery, The University of Texas MD Anderson Cancer Center, 2023 - 2024

Member, Core Facilities Oversight Board (Core Equipment), The University of Texas MD Anderson Cancer Center, 2022 - 2026

Member, Interview Panel Member: MD/PhD Student Admissions Interview, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, Brain Tumor Program Data Governance Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2023

Co-Lead, Radiosurgery Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, Brain Tumor Program Tissue Utilization Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, Brain Metastasis Clinic, The University of Texas MD Anderson Cancer Center, 2020 - Present

Member, TMC3 Science Think Tank, The University of Texas MD Anderson Cancer Center, 2020 - 2023

Editorial Activities

Associate Editor, BMC Biomedical Engineering, 2018 - 2022

Early Careers Editorial Board, Nano Letters, 2016 - 2019

Associate Editor, Frontiers in Neurology, 2016 - 2017

Associate Editor, BMC Cancer, 2015 - 2019

Honors & Awards

2026 - Present	Nobility in Science, Oligo Nation
2024	Elected Fellow, American Society for Clinical Investigation
2023	Regina Rogers Family Award, The University of Texas MD Anderson Cancer Center
2023	Elected Fellow, American Institute for Medical and Biological Engineering (AIMBE)
2022	Texas Business Women's Award, Texas Business and Professional Women's Foundation
2021	Sabin Family Foundation Fellowship Award, Sabin Family Foundation
2016	Forty Stars of Forty Under Florida - Florida Trend Magazine
2012	Detweiler Travelling Fellowship - Royal College of Physicians and Surgeons
2010	Sopman Humanitarian Award - University of Toronto
2009	National Research Award for Specialty Residents - Royal College of Physicians
2009	Mark Bernstein Award in Neurosurgery - University of Toronto, Toronto, Canada
2009	National Research Award - Canadian Federation of University Women, First place
2009	Top Gun American Association of Neurological Surgeons, 1st place
2008 - 2009	AANS/NREF Fellowship - American Association of Neurological Surgeons
2008 - 2009	Restracomp Research Training Grant - Hospital for Sick Children, 1st place
2008	CIHR/Brain Star Award - Canadian Institutes of Health Research, Best research
2008	Joseph M. West Family Memorial Scholarship - University of Toronto
2008	McKenzie Award - Canadian Neurological Sciences, Best neuroscience research
2008	Thomas Morley Best Original Research - University of Toronto
2008	Time Posters Fellowship - University of Toronto School of Medicine
2008	Gallie-Bateman Research Award - Department of Surgery, University of Toronto
2008	Javenthey Soobiah Scholarship - University of Toronto School of Medicine
2005 - 2008	Natural Sciences & Engineering Research Canada (NSERC) Grant
2005	Joseph M. West Family Memorial Fund - University of Toronto
2005	Post-Graduate Medicine Research Award - University of Toronto
2005	Price Water House Research Excellence Award - University of Toronto
2005	Thomas L. Friedlich Award in Surgical Sciences Research - University of Toronto
2005	Charles F. Fell Scholarship - University of Toronto School of Medicine
2005	Heart and Stroke and Foundation of Canada - Medical Research Scholar Award
2005	Chisholm Memorial Research Fellowship

Professional Memberships

American Society for Clinical Investigation

2024 - Present

American Institute for Medical and Biological Engineering

2023 - Present

Neurosurgical Society of America

2019 - Present

American Association for the Advancement of Science

2016 - Present

American Brain Tumor Association

2014 - Present

American Association of Cancer Research

2013 - Present

Royal College of Physicians and Surgeons of Canada

2013 - Present

World Federation of Neurological Surgeons

2007 - Present

American College of Surgeons

2007 - Present

Women in Neurosurgery

2006 - Present

Congress of Neurological Surgeons

2005 - Present

Society for Neuro-Oncology

2005 - Present

American Association of Neurological Surgeons

2002 - Present

Selected Presentations & Talks

Local Presentations

2025. Messages in a vesicle: mRNA therapy for cancer and other human diseases. Invited. Division of Cancer Medicine Grand Rounds. Houston, Texas, US.
2024. A Novel mRNA Delivery Platform. Invited. Horizons Meeting. Houston, Texas, US.
2024. Immune-Engineering Approaches for Cancer Therapy. Invited. MCO Distinguished Scientist Seminar Series. Houston, Texas, US.
2023. Targeting phagocytosis against cancer and other human diseases. Conference. Targeting phagocytosis against cancer and other human diseases. Houston, TX, US.
2021. Translating Discoveries in Neurosurgical Oncology. Conference. Translating Discoveries in Neurosurgical Oncology, US.
2021. Targeting Phagocytosis as a New Cancer Immunotherapy. Conference. Targeting Phagocytosis as a New Cancer Immunotherapy. Virtual, US.

Regional Presentations

2023. Development of an Independent Research Program. Conference. Development of an Independent Research Program, TX, US.
2022. Targeting phagocytosis for cancer immunotherapy. Conference. Targeting phagocytosis for cancer immunotherapy, TX, US.
2015. Vasculature remodeling enhances intermediate-sized nanoparticle delivery into solid tumors. Conference. Vasculature remodeling enhances intermediate-sized nanoparticle delivery into solid tumors. Orlando, FL, US.
2014. Nanomedicine for brain tumors. Conference. Nanomedicine for brain tumors. Jacksonville, FL, US.

National Presentations

2025. Messages in a vesicle: mRNA therapy for cancer and other human diseases. Invited. TCI Seminar Series. New York City, New York, US.
2024. Immuno-Engineering for Cancer Therapeutics. Visiting. Grand Rounds Lecture Winship Cancer Institute. Decatur, GA, US.
2023. Designing nanomaterials for immune modulation. Conference. Gordon Research Conference: Cancer Nanotechnology, NH, US.
2023. Clinical Trials for Brain Tumors. Conference. Clinical Trials for Brain Tumors. Chicago, IL, US.
2023. Tumor microenvironment modulation by immunotherapy sensitizes solid tumors to radiation. Conference. Tumor microenvironment modulation by immunotherapy sensitizes solid tumors to radiation. Orlando, FL, US.
2023. NL201 a de novo CD25-independent IL2RbG agonist, synergies with radiation to generate potent anti tumor immunity. Conference. NL201 a de novo CD25-independent IL2RbG agonist, synergies with radiation to generate potent anti tumor immunity. Orlando, FL, US.
2023. Development of cationic helical polypeptide-based adjuvants for cancer immunotherapy. Conference. *Sygnature Discovery Scholar-in-Award. Orlando, FL, US.
2023. Breakout Stars in Science - STAT Wunderkind. Conference. STAT News. Boston, MA, US.
2022. Applying Immuno-Engineering Concepts for Cancer Immunotherapy. Conference. Applying Immuno-Engineering Concepts for Cancer Immunotherapy. Dallas, TX, US.
2022. Cancer Immunology - Moderator. Conference. Cancer Immunology - Moderator. Dallas, TX, US.
2022. BioInnovations in Brain Cancer. Conference. BioInnovations in Brain Cancer. Ann Arbor, MI, US.
2022. Social Media and Career Development. Conference. MD Anderson Research Town Hall. Houston, TX, US.
2021. Unleashing the Immune System to Develop Therapeutic Strategies. Conference. Unleashing the Immune System to Develop Therapeutic Strategies, TX, US.
2021. ABTA Discovery Grant Presentation. Conference. ABTA Discovery Grant Presentation. Virtual, US.
2021. Nanomaterials for immunomodulation- a virtual Panel Discussion hosted by Nature Nanotechnology. Conference. Nanomaterials for immunomodulation- a virtual Panel Discussion hosted by Nature Nanotechnology. Virtual, US.
2021. Breakthrough Delivery Science. Conference. Breakthrough Delivery Science. Keynote Speaker, US.
2021. Break Through Cancer GBM Team. Conference. MD Anderson Research Town Hall. Houston, TX, US.
2020. Therapeutic modulation of phagocytosis in glioblastoma activates both innate and adaptive antitumor immunity. Conference. Therapeutic modulation of phagocytosis in glioblastoma activates both innate and adaptive antitumor immunity. Kiawah Island, SC, US.
2020. Targeting brain tumors using therapeutic exosomes. Conference. Targeting brain tumors using therapeutic exosomes. Houston, TX, US.
2019. Novel approaches to glioblastoma therapy using the innate immune system. Conference. Novel approaches to glioblastoma therapy using the innate immune system. Orlando, FL, US.
2018. Re-engineering the immune tumor microenvironment with nanomaterials. Visiting. Re-engineering the immune tumor microenvironment with nanomaterials. Oklahoma City, OK, US.
2017. Selective macrophage-evading nanomedicine as a new targeted drug delivery strategy. Conference. Selective macrophage-evading nanomedicine as a new targeted drug delivery strategy. Mount Snow, RI, US.
2017. Normalizing the tumor microenvironment for enhanced nanomedicine delivery. Conference. Angiogenesis and Tumor Microenvironment Symposium. Amelia Island, FL, US.
2017. Priming of the brain tumor microenvironment to enable nanomedicine delivery. Conference. Priming of the brain tumor microenvironment to enable nanomedicine delivery. San Diego, CA, US.
2017. Re-engineered brain imaging Convergence Technology Summit. Conference. Re-engineered brain imaging Convergence Technology Summit. Atlanta, GA, US.
2017. Blockade of stearoyl CoA desaturase 1 promotes immunogenic clearance of tumors. Conference. Blockade of stearoyl CoA desaturase 1 promotes immunogenic clearance of tumors. Washington, DC, US.
2017. CD47 blockade with temozolomide can enhance the therapy in glioblastoma. Conference. CD47 blockade with temozolomide can enhance the therapy in glioblastoma. Washington, DC, US.
2017. Priming of the tumor microenvironment enables improved nanomedicine delivery. Conference. Priming of the tumor microenvironment enables improved nanomedicine delivery. Mount Snow, RI, US.

International Presentations

2025. Messages in a vesicle: mRNA therapy for cancer and other human diseases. Invited. Tokyo, JP.
2025. Novel Immuno-Engineering Approaches for Cancer. Conference. Bhubaneswar, IN.
2024. mRNA Delivery to Replete Tumor Suppressor Genes in Brain Tumors. Conference. Lisbon, PT.
2024. Bioengineering Gene Delivery for Cancer Therapeutics. Visiting. Oxfordshire, GB.
2023. Targeting phagocytosis against cancer and other human diseases. Conference. Centro di Riferimento Oncologico (CRO). Aviano, IT.
2021. Predictors of overall survival (OS) in patients (pts) with melanoma brain metastasis (MBM) in the modern era. Conference. Predictors of overall survival (OS) in patients (pts) with melanoma brain metastasis (MBM) in the modern era. Virtual, US.
2016. Modulating the tumor microenvironment to improve immunotherapy. Conference. Modulating the tumor microenvironment to improve immunotherapy. Dublin, IE.

Formal Peers

2022. Pursuing a career as a surgeon scientist. Invited, US.
2022. Targeting phagocytosis as a novel strategy for cancer immunotherapy. Invited, MI, US.
2021. Neurosurgical Technologies for Bioengineers. Visiting. Chicago, IL, US.
2021. Cancer Nanotechnology. Invited. Champaign, IL, US.
2021. Modulation of the innate immunity as a therapy for Brain Tumors. Visiting, US.
2021. Topics in Molecular Medicine. Visiting. Houston, TX, US.
2021. Translating Discoveries in Neurosurgical Oncology. Invited. Dallas, TX, US.
2020. Bioengineering Seminar Series. Invited. Cambridge, MA, US.
2019. Bridging innate and adaptive anti-tumor immunity via therapeutic induction of targeted cancer cell phagocytosis. Visiting. San Francisco, CA, US.
2018. Cancer Therapy without Targeting Cancer Cells. Visiting. Dallas, TX, US.
2018. 4-D Visualization of the Brain. Visiting. Durham, NC, US.
2018. Tumor immune-reprogramming with rationally-designed nanomedicines. Visiting. Gainesville, FL, US.
2018. Taming phagocytosis to enhance cancer immunotherapy. Visiting. Durham, NC, US.
2018. Brain immune-microenvironment modulation for therapy. Visiting. Indianapolis, IN, US.
2016. Vascular normalization for enhanced CNS drug delivery. Invited. Rochester, MN, US.
2015. Reaching your true potential: a hitchhiker's guide to brain surgery and beyond. Visiting. Orlando, FL, US.
2015. Engineering of the brain tumor microenvironment using nanoparticle design. Invited. Chicago, IL, US.
2013. Neurosurgical nanotechnology: Targeting brain tumors and beyond National Institute of Neurological Disorders and Stroke (NINDS). Invited. Bethesda, MD, US.
2013. Nanotechnology for brain tumors: The future is now. Visiting. Jacksonville, FL, US.
2013. Nano neuro-oncology: There's plenty of room at the top too. Visiting. Montreal, CA.
2013. Nanotechnology for the neurosurgeon: The time is now. Visiting. Portland, OR, US.
2012. Nanogeometry: Drug targeting and beyond. Visiting. Houston, TX, US.

Less

Grant & Contract Support

Date:	2026 - 2029
Title:	Developing a first-in-class, non-cytotoxic, humanized antibody-drug conjugate for inflammatory breast cancer immunotherapy
Funding Source:	DOD
Role:	Co-I
ID:	BC250995

Date:	2026 - Present
Title:	Andrew Sabin Family Excellence Endowment of the Allison Institute
Funding Source:	James P Allison Institute
Role:	PI

Date:	2025 - 2027
Title:	Engineering next-generation mRNA vaccines for oligodendroglioma
Funding Source:	OligoNation
Role:	PI

Date:	2025 - 2027
Title:	Engineering a microbial-inspired antibody toxin bioconjugate for cancer immunotherapy
Funding Source:	CPRIT
Role:	PI
ID:	RP250526

Date:	2025 - 2030
Title:	Microbial-inspired immune-stimulating antibody-toxin conjugate for cancer immunotherapy
Funding Source:	NCI
Role:	PI
ID:	1R01CA305986-01

Date:	2025 - 2028
Title:	Engineering second generation in vivo chimeric antigen receptor macrophages (CARMs) for glioblastoma therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI
ID:	RP230307

Date:	2024 - 2026
Title:	Engineering in vivo chimeric antigen receptor macrophages for diffuse midline glioma
Funding Source:	CPRIT
Role:	Co-I
ID:	RP240493

Date:	2024 - 2029
Title:	Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastoma
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	1R01CA291876-01

Date:	2023 - 2027
Title:	Engineering in vivo chimeric antigen receptor macrophages (CARMs) using mRNA-exosomes for cancer immunotherapy
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	1R01CA284108-01

Date:	2022 - 2024
Title:	Microbial mediated STING Activation for Glioblastoma Immunotherapy
Funding Source:	American Brain Tumor Association
Role:	Mentor

Date:	2022 - 2024
Title:	Reversing aging-associated resistance to cancer immunotherapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI

Date:	2022 - 2026
Title:	Glioblastoma immunotherapy with dual phagocytosis checkpoint blockade
Funding Source:	American Cancer Society
Role:	Co-I
ID:	2021ACS000RSG0000218113

Date:	2022 - 2024
Title:	Microbial-inspired STING Activation for Glioblastoma Immunotherapy
Funding Source:	Uncle Kory Foundation
Role:	PI

Date:	2022 - 2026
Title:	Break Through Cancer Glioblastoma Team
Funding Source:	Research Alliance between MIT, Dana Farber, MD Anderson, Memorial Sloan Kettering and Johns Hopkins University
Role:	Co-I

Date:	2021 - 2023
Title:	Aging, cancer and the fountain of immunological youth: The effect of aging on cancer immunotherapy
Funding Source:	Sabin Fellowship Award
Role:	PI

Date:	2021 - 2026
Title:	Therapeutic targeting of multiple glioblastoma phagocytosis checkpoints using a novel bispecific antibody
Funding Source:	NIH/NINDS
Role:	Co-I
ID:	1R01NS117828-01A1

Date:	2021 - 2026
Title:	S100a4 Mediated Immune Suppression in GBM
Funding Source:	NIH/NINDS
Role:	Co-I
ID:	1R01NS121405-01

Date:	2020 - 2023
Title:	Clinical Development of CAR T Cell Therapy Targeting CD70 in Primary Glioblastoma
Funding Source:	DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role:	Co-I
ID:	W81XWH-20-1-0726

Date:	2019 - 2024
Title:	SPORE in Brain Cancer – Animal Core
Funding Source:	NIH/NCI
Role:	Project Leader
ID:	2 P50 CA127001-11A1

Date:	2019 - 2023
Title:	Microfluidics-array based sorting, isolation and RNA analysis of single extracellular vesicles
Funding Source:	NIH/NCATS
Role:	Co-PI
ID:	1UG3 TR002884 -02

Date:	2019 - 2022
Title:	A fusion protein bispecific phagocyte engager for targeted breast cancer immunotherapy
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	BC180673

Date:	2019 - 2021
Title:	Microfluidics-array based sorting, isolation and RNA analysis of single extracellular vesicles
Funding Source:	NIH/NCATS
Role:	PI
ID:	1UG3TR002884-01

Date:	2018 - 2023
Title:	Therapeutic modulation of the phagocytosis axis as a novel glioblastoma immunotherapy
Funding Source:	NIH/NINDS
Role:	PI
ID:	1R01NS104315A

Date:	2018 - 2021
Title:	Impact of ApoE2 on age-related conditions
Funding Source:	NIH/NIA
Role:	Co-I
ID:	R01AG57191

Date:	2018 - 2019
Title:	Multivalent Biologics for Immune Detection of Cancer
Funding Source:	Zymeworks Inc
Role:	PI
ID:	BU00167857

Date:	2018 - 2019
Title:	A Novel Bi-Specific Antibody for Glioblastoma Immunotherapy
Funding Source:	Merck-EMD Serono
Role:	PI
ID:	BU00154360

Date:	2018 - 2019
Title:	Enhancing Cancer Immunotherapy
Funding Source:	Mayo Clinic Department of Business Development
Role:	PI
ID:	BU91574017

Date:	2017 - 2021
Title:	Pathogenic effects of plasma ApoE on CNS function and Alzheimer's Disease
Funding Source:	NIH/NIA R21
Role:	Co-I
ID:	1R21AG057981

Date:	2017 - 2019
Title:	Advanced Iimmune-Nano Imaging for Cancer Therapy
Funding Source:	Mayo Clinic Strawn Family Research Award
Role:	PI
ID:	91574002

Date:	2017 - 2019
Title:	GABA Reactivates Hepatocytes in Aged Liver
Funding Source:	NIH/NIA R21
Role:	Co-I
ID:	1R21AG052822

Date:	2017 - 2019
Title:	Engineering a Bi-Specific Nano-Engager for Targeted Glioblastoma Immunotherapy
Funding Source:	Florida Center for Brain Tumor Research
Role:	PI
ID:	UFDSP00011933

Date:	2016 - 2019
Title:	Nanomedicines for Cancer Theranostics
Funding Source:	Mayo Clinic DeMars Award for Nanomedicine
Role:	PI
ID:	91574002

Date:	2016 - 2019
Title:	High Throughput Multiplexed Immunological Profiling of Glioblastoma using Nano-Bioconjugates
Funding Source:	Mayo Clinic Helene Houle Award for Neurologic Surgery
Role:	PI
ID:	91574009

Selected Publications

Peer-Reviewed Articles

Chang M, Wang Y, Ha JH, Neale Z, Ajami N, Diggs L, Ma Y, Dong S, Sharma P, Wargo J, Jiang W, Goswami S, Schrank B, Jeong SD, Kim BYS. A transferable gut microbiota-bile acid pathway programs nanomedicine pharmacokinetics and therapeutic response. Nature Materials, 2026. e-Pub 2026.
Chang M, Wang Y, Ha J, Neale ZR, Ajami NJ, Diggs LP, Nalin AP, Ma Y, Dong S, Hoballah YM, Day A, Jeong SD, Wu A, Schrank BR, Edwards JL, Wang T, Wang X, Chang YT, Tang C, Lim AJ, Torres MN, Deng W, Peitsch T, Dufilho MJ 4th, Goswami S, Jiang D, Koong AC, Sharma P, Wargo JA, Jiang W, Kim BYS. A transferable gut microbiota-bile acid pathway programs nanomedicine pharmacokinetics and therapeutic response. Nat Mater 25(9):1634-1645, 2026. e-Pub 2026. PMID: 42538384.
Catalino MP, Suki D, Ballester L, Andersen CR, Ramadoss P, Prabhu SS, Weinberg JS, Poon CC, Cezayirli PC, Brahimaj B, McCutcheon IE, Ferguson SD, Ene CI, Kim BYS, Raza SM, Demonte F, Lang FF. Extent of resection as an independent predictor of survival for patients with glioblastoma as defined by the new WHO 2021 classification. J Neurosurg:1-11, 2026. e-Pub 2026. PMID: 42398118.
Wang X, Kim BYS. Senescent B cells accumulate in germinal centre niches of the aged human lymph node. Nat Rev Immunol 26(7):487, 2026. e-Pub 2026. PMID: 42225883.
Tian Y, Liu Y, Tong Y, Huntoon K, Yang L, Shi J, Ma Y, Dong S, Jeong SD, Estania AP, Yi Y, Kwak KJ, Wang Y, Wu A, Edwards JL, Wang X, Chang YT, Cao J, Zhang H, Sun M, Grippin AJ, Yang Z, Lu WJ, Lee LJ, Bahrani E, Zhang H, Bai L, Nguyen PK, Jiang W, Lan F, Kim BYS, Lee AS. Skeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy. Nat Biomed Eng, 2026. e-Pub 2026. PMID: 42277318.
Ha J, Wang Y, Ma Y, Wu A, Dong S, Jeong SD, Edwards JL, Chang M, Chang YT, Wang X, Dufilho M, Najarro Torres M, McCabe S, Deng W, Grippin AJ, Weinberg JS, Raza SM, DeMonte F, McCutcheon IE, Prabhu S, Ferguson SD, Ene CI, Akdemir K, Basu S, Jindal S, Schrank BR, Hu J, Goswami S, Puduvalli VK, Lang FF, Huntoon K, Sharma P, Kim BYS, Jiang W. Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma. Nat Communications, 2026. e-Pub 2026. PMID: 41803138.
Wu A, Kim BYS. Affinity-dependent local antibody feedback shapes germinal centre dynamics. Nat Rev Immunol 26(3):169, 2026. e-Pub 2026. PMID: 41651930.
Beckham TH, Dudzinski SO, Rooney MK, Faraj CA, Pasli M, Perni S, Tom M, Ghia A, Yeboa DN, McAleer MF, Swanson T, McGovern S, Wang C, Chung C, De B, Jiang W, Kim BYS, Ferguson SD, Tawbi HA, Glitza I, Le X, Kaya D, Dumbrava EE, Briere T, Mackin D, Li J. Incorporating an NCCN-Based Systemic Therapy CNS Activity Score Into SRS Decision-Making for Patients With 5 or More Brain Metastases. J Natl Compr Canc Netw 24(2):34-40, 2026. e-Pub 2026. PMID: 41671425.
Zhang H, Sun M, Chen J, Wang S, Liu J, Yang H, Liu L, Hu S, Yang F, Teng L, Chen Z, Wang X, Dong S, Ma Y, Edwards JL, Wang X, Chang YT, Kim BYS, Jiang W, Cui Y, Yang Z. Immunological conversion of triple-negative breast cancer by engineered extracellular vesicle-mediated pyroptosis. J Control Release 389:114493, 2026. e-Pub 2026. PMID: 41344487.
Zhang, H, Xing, J, Sun, M, Cui, Y, Li, Y, Hu, S, Wang, X, Jiang, H, Zhang, Y, Jiang, X, Yang, F, Kim, BYS, Jiang, W, Yang, Z, Teng, L. Engineered exosomes for targeted microRNA delivery to reverse liver fibrosis. Biomaterials 324, 2026. e-Pub 2026. PMID: 40561654.
Zhao L, O'Donnell KL, Dubey M, Wang Y, Martinez NR, Zhang Y, Steininger HM, Ma C, Mallajosyula V, Lee LLY, Lachmansingh RN, Stavitsky S, Takematsu E, Hoover MY, Chen H, Guo J, Wu A, Ma Y, Wang X, Nalin AP, Jeong SD, Lu WJ, Nguyen PK, Clancy CS, Tal MC, Xiao J, Longaker MT, Lee AS, Kim BYS, Ambrosi TH, Weissman IL, Davis MM, Hasenkrug KJ, Chien YH, Jiang W, Marzi A, Chan CKF. Engineered mucus-tethering bispecific nanobodies enhance mucosal immunity against respiratory pathogens. Nat Nanotechnol, 2026. e-Pub 2026. PMID: 41565781.
Yu, K, Basu, S, Baquer, G, Ahn, R, Gantchev, J, Jindal, S, Regan, MS, Abou-Mrad, Z, Prabhu, MC, Williams, MJ, D’Souza, AD, Malinowski, S, Hopland, K, Elhanati, Y, Stopka, SA, Stortchevoi, A, Couturier, C, He, Z, Sun, JJ, Chen, Y, Espejo, A, Chow, KH, Yerrum, S, Kao, PL, Kerrigan, BP, Norberg, L, Nielsen, D, Douville, C, Sharma, P, Giantini-Larsen, AM, Hu, J, Ayoub, G, Elharouni, D, Polk, MJ, Landivar, AM, Masud, N, Ling, AL, Triggs, D, Piranlioglu, R, Ball, A, Soni, H, Solomon, IH, Vasquez, KL, Vogelzang, J, Puduvalli, VK, Huse, J, Kim, BYS, Goswami, S, Lang Jr, FF, Sharma, P. Investigative needle core biopsies support multimodal deep-data generation in glioblastoma. Nature communications 16(1), 2025. e-Pub 2025. PMID: 40295505.
Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A, Jeong SD, Soni D, Weidert F, Xie C, Goldenberg E, Kim A, Zhao C, DeVries A, Castillo P, Lohray R, Rooney MK, Schrank BR, Wang Y, Ma Y, Chang E, Kouzy R, Dyson K, Jafarnia J, Nariman N, Gladish G, New J, Argueta A, Amaya D, Thomas N, Doty A, Chen J, Copling N, Alatrash G, Simon J, Davies AB, Dennis W, Liang R, Lewis J, Wei X, Rinsurongkawong W, Vaporciyan AA, Johns A, Lee J, Lee JH, Sun R, Sharma P, Tran H, Zhang J, Gibbons DL, Wargo J, Kim BYS, Heymach JV, Mendez-Gomez HR, Jiang W, Sayour EJ, Lin SH. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647(8089):488-497, 2025. e-Pub 2025. PMID: 41125896.
Hou M, Ma Y, Deng Y, Wu Y, Zhu Y, Liu Y, Li X, Yu L, He Z, Wang Y, Dong S, Xia X, Yu J, Yu C, Kang K, Lu Y, Sun L, Kim BYS, Yuan Y, Zhang Y, Jiang W, Zhu X. Therapeutic restoration of mitochondria-endoplasmic reticulum crosstalk for osteoarthritis. Proc Natl Acad Sci U S A 122(36):e2426992122, 2025. e-Pub 2025. PMID: 40892916.
Sun M, Zhang H, Ma Y, Wang S, Chen J, Cui Y, Zhang Y, Hu S, Zhou D, Zhang P, Liu Y, Kim BYS, Jiang W, Wang X, Yang Z. In Situ Programming of the Tumor Microenvironment to Alleviate Immunosuppression for Pancreatic Cancer Immunotherapy. Adv Sci (Weinh) 12(34):e04008, 2025. e-Pub 2025. PMID: 40548883.
Tao H, Chen D, Yang C, Nguyen DT, Abboud G, Liu R, Liu T, Chakraborty A, Hou AY, Petit NA, Abbas M, Davis RW, Zhang J, Von Roemeling C, Gbadamosi MO, Jin L, Gu T, Lin T, Wang P, Pepe A, Pedro DI, Mendez-Gomez HR, Xie C, Karachi A, Weidert F, Jin D, Wang C, Long-James K, Molchan EK, Castillo P, Ligon JA, Ghiaseddin AP, Sayour EJ, Rahman M, Deleyrolle LP, Kim BY, Mitchell DA, Sawyer WG, Huang J. Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response. J Clin Invest 135(16), 2025. e-Pub 2025. PMID: 40591413.
Grippin, A, Lee, DY, Parkes, EE, Jiang, W, Kim, YB. Nanotechnology for immuno-oncology. Nature Cancer 6(8):1311-1325, 2025. e-Pub 2025. PMID: 40775548.
Yeboa DN, Li J, Lin R, Prabhu SS, Beckham TH, Woodhouse K, Swanson TA, Weinberg JS, Wang X, Chi X, Ejezie CL, Suki D, Wang C, Ene C, McCutcheon IE, McGovern S, McAleer MF, Tom M, Ghia A, Perni S, Jiang W, De B, Chung C, Kim BYS, O'Brien BJ, Huse JT, Wefel JS, Court L, Tawbi H, Janku F, Guha-Thakurta N, Debnam JM, Johnson J, Taslicay CA, Alvarez-Breckenridge C, Raza SM, Heimberger AB, DeMonte F, North R, Briere TM, de Groot JF, Sawaya R, Grosshans D, Lang FF, Rao G, Ferguson SD. Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical Trial. JAMA Oncol 11(8):890-899, 2025. e-Pub 2025. PMID: 40531511.
Zhang A, Ma Y, Liu Y, Dong S, Torres MN, Kim BYS, Liu C, Sun L, Yuan Y, Jiang W. Mannose Oligosaccharide-Conjugated In Situ Pore-Forming Injectable Hydrogels for Rheumatoid Arthritis Treatment by Reprogramming Macrophage Extracellular Vesicles. Small Methods 10(3), 2025. e-Pub 2025. PMID: 40662273.
Khorsandi S, Huntoon K, Wang Y, Woodward A, Antony A, Endsley C, Hafeez N, Edwards JL, McCuen N, Alluri PG, Kim BYS, Jiang W, Lux J. Targeted STING Activation Using Modified Ultrasound-Responsive Microbubbles Enhances Immune Checkpoint Blockade Against Melanoma. Adv Sci (Weinh) 12(22):e2416596, 2025. e-Pub 2025. PMID: 40135812.
Wang, Y, Song, H, Teng, Y, Huang, G, Qian, J, Wang, H, Dong, S, Ha, JH, Ma, Y, Chang, M, Jeong, S, Deng, W, Schrank, B, Grippin, A, Wu, A, Edwards, J, Zhang, Y, Lin, Y, Poon, W, Wilhelm, S, Bi, Y, Teng, L, Wang, Z, Kim, YB, Jiang, W. A Generative Artificial Intelligence Copilot for Biomedical Nanoengineering. ACS Nano 19(20):19394-19407, 2025. e-Pub 2025. PMID: 40367350.
You, Y, Tian, Y, Guo, R, Shi, J, Kwak, KJ, Tong, Y, Estania, AP, Hsu, WH, Liu, Y, Hu, S, Cao, J, Yang, L, Bai, R, Huang, P, Lee, LJ, Jiang, W, Kim, BYS, Ma, S, Liu, X, Shen, Z, Lan, F, Phuong Nguyen, PK, Lee, AS. Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity. European heart journal 46(17):1662-1676, 2025. e-Pub 2025. PMID: 39831819.
Kim BY, Tang Z, Niu M, Kuang Z, Xue W, Wang X, Liu X, Yu Y, Jeong SD, Ma Y, Wu A, Kim BYS, Jiang W, Yang Z, Li C. Allosteric targeted drug delivery for enhanced blood-brain barrier penetration via mimicking transmembrane domain interactions. Nature Communications, 2025. e-Pub 2025. PMID: 40210849.
Gao F, Liu X, Ma Z, Tang M, Tang Z, Wu J, Luo M, Tang Y, Wang X, Wang B, Kim BYS, Yang Z, Jiang W, Tang P, Li C. An Integrated Modular Vaccination System for Spatiotemporally Separated Perioperative Cancer Immunotherapy. Adv Mater 37(11):e2418322, 2025. e-Pub 2025. PMID: 39924759.
Schrank BR, Wang Y, Wu A, Tran N, Lee D, Edwards J, Huntoon K, Dong S, Ha J, Ma Y, Grippin AJ, Jeong SD, Antony A, Chang M, Kang M, Gallup TD, Koong AC, Li J, Yun K, Kim BYS, Jiang W. An antibody-toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy. Nat Cancer, 2025. e-Pub 2025. PMID: 40000910.
Wang Y, Xiao Z, Wang Z, Lee DY, Ma Y, Wilhelm S, Wang H, Kim BYS, Jiang W. Multi-omics approaches to decipher the interactions of nanoparticles and biological systems. Nature Reviews Bioengineering, 2024. e-Pub 2024.
Wang Y, Schrank BR, Jiang W, Kim BYS. Learning what keeps nanomedicines in tumours. Nat Biomed Eng, 2024. e-Pub 2024. PMID: 39271934.
Huntoon, K, Lee, DY, Dong, S, Antony, A, Kim, YB, Jiang, W. Targeting phagocytosis to enhance antitumor immunity. Trends in Cancer 10(6):571, 2024. e-Pub 2024. PMID: 37839974.
Beckham, TH, Dudzinski, SO, Pasli, M, Perni, S, Tom, MC, Ghia, AJ, Yeboa, DN, McAleer, MF, Swanson, T, McGovern, SL, Wang, C, Chung, C, Briere, TM, An, R, De, BS, Glitza, IC, Kim, YB, McCutcheon, IE, Ferguson, SD, Li, J. Radiosurgery to 5 or more newly diagnosed brain metastases in the systemic therapy era. Journal of Clinical Oncology 42(16):2026, 2024. e-Pub 2024.
Sun L, Niu H, Wu Y, Don S, Li X, Kim BYS, Liu C, Ma Y, Jiang W, Yuan Y. Bio-integrated scaffold facilitates large bone regeneration dominated by endochondral ossification. Bioactive Materials 35(1):208-227, 2024. e-Pub 2024. PMID: 38327823.
Bian X, Yang L, Jiang D, Grippin AJ, Ma Y, Wu S, Dong S, Kim BYS, Jiang W, Yang Z, Li C. Regulation of cerebral blood flow boosts precise brain targeting of vinpocetin-derived ionizable-lipidoid nanoparticles. Nature Communications 15(1):3987, 2024. e-Pub 2024. PMID: 38734698.
Ene CI, Abi Faraj C, Beckham TH, Andersson CR, Kim BYS, McCutcheon IE, Prabhu SS, McGovern SL, Tom MC, Perni S, Swanson TA, Yeboa DN, Briere TM, Huse JT, Sawaya RE. Response to treatment-naive brain metastases to stereotactic Radiosurgery. Nature Communications 15:3728, 2024. e-Pub 2024.
Lee DY, Huntoon K, Wang Y, Lu Y, Qie Y, Li X, Dong S, Yang Z, Wang L, Li J, Koong A, Jiang W, Kim BYS. Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nature Biomedical Engineering, 2024. e-Pub 2024. PMID: 38641710.
LI X, Huntoon K, Wang Y, Lee DY, Dong S, Antony A, Walkey C, Kim BYS, Jiang W. Radiation synergizes with IL2/IL15 stimulation to enhance innate immune activation and antitumor immunity. Mol Cancer Ther 23(3):330-342, 2024. e-Pub 2024. PMID: 37956421.
Wang Y, Deng W, Lee DY, Yan L, Yang M, Gong P, Huntoon K, Lu Y, Lorenzi P, Yang Z, Kim BYS, Jiang W. Age-associated disparity in phagocytic clearance affects the efficacy of cancer nanotherapeutics. Nature Nanotechnology 19(2):255-263, 2024. e-Pub 2024. PMID: 37723279.
Chiang, C, Ma, Y, Hou, YC, Pan, JJ, Chen, SY, Chien, MH, Zhang, ZX, Hsu, WH, Wang, X, Zhang, J, Li, H, Sun, L, Fallen, S, Lee, I, Chen, XY, Chu, YS, Zhang, C, Cheng, TS, Jiang, W, Kim BYS, Reátegui, E, Lee, RJ, Yuan, Y, Liu, HC, Wang, K, Hsiao, M, Huang, CY, Shan, YS, Lee, AS, Lee, LJ. Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer. Nature Communications 14(1), 2023. e-Pub 2023. PMID: 37872156.
Zhang, J, Rima, XY, Wang, X, Nguyen, LT, Huntoon, K, Ma, Y, Palacio, PL, Nguyen, KT, Albert, K, Duong-Thi, MD, Walters, N, Kwak, KJ, Yoon, MJ, Li, H, Doon-Ralls, J, Hisey, CL, Lee, DY, Wang, Y, Ha, JH, Scherler, K, Fallen, S, Lee, I, Palmer, AF, Jiang, W, Magaña, SM, Wang, K, Kim BYS, Lee, LJ, Reátegui, E. Engineering a tunable micropattern-array assay to sort single extracellular vesicles and particles to detect RNA and protein in situ. Journal of Extracellular Vesicles 12(11), 2023. e-Pub 2023. PMID: 37908159.
Liu, CC, Wang, N, Chen, Y, Inoue, Y, Shue, F, Ren, Y, Wang, M, Qiao, W, Ikezu, TC, Li, Z, Zhao, J, Martens, YA, Doss, SV, Rosenberg, CL, Jeevaratnam, S, Jia, L, Raulin, AC, Qi, F, Zhu, Y, Alnobani, A, Knight, JA, Chen, Y, Linares, C, Kurti, A, Fryer, JD, Zhang, B, Wu, LJ, Kim BYS, Bu, G. Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer’s disease. Nature Immunology 24(11):1854-1866, 2023. e-Pub 2023. PMID: 37857825.
Dong S, Liu X, Bi Y, Wang Y, Antony A, Lee D, Huntoon K, Jeong S, Ma Y, Li X, Deng W, Schrank BR, Grippin AJ, Ha J, Kang M, Chang M, Zhao Y, Sun R, Sun X, Yang J, Chen J, Tang SK, Lee LJ, Lee AS, Teng L, Wang S, Teng L, Kim BYS, Yang Z, Jiang W. Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer. Nature Communications 14(1):6610, 2023. e-Pub 2023. PMID: 37857647.
Altan M, Wang Y, Song J, Welsh J, Tang C, McGovern SL, Wang C, Kim BYS, Weinberg J, Cascade T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. Journal for Immunotherapy of Cancer (JITC), 2023. e-Pub 2023. PMID: 37402581.
Hasanov M, Milton DR, Davies AB, Sirmans E, Saberian C, Posada EL, Opusunju S, Gershenwald JE, Torres-Cabala CA, Burton EM, Colen RR, Huse JT, Glitza Oliva IC, Chung C, McAleer MF, McGovern SL, Yeboa DN, Kim BYS, Prabhu SS, McCutcheon IE, Weinberg JS, Lang FF, Tawbi HA, Li J, Haydu LE, Davies MA, Ferguson SD. Changes in outcomes and factors associated with survival in melanoma patients with brain metastases. Neuro Oncol 25(7):1310-1320, 2023. e-Pub 2023. PMID: 36510640.
You Y, Tian Y, Yang Z, Shrank B, Huntoon K, Lee D, Gallup T, Ha J, Wang Y, Lee L, Jiang W, Kim BYS, Lan F, Lee A. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nature Biomedical Engineering 7(7):887-900, 2023. e-Pub 2023. PMID: 36635419.
Huntoon K, Anderson K, Ballman K, Twohyu E, Jiang W, Li J, von Roemeling C, Qie Y, Laack N, Brown P, Roberge D, Kim BYS. Association of circulating markers with cognitive decline after radiation therapy for brain metastasis. Neuro-Oncology 25(6):1123-1131, 2023. e-Pub 2023. PMID: 36472389.
Oue H, Yamazaki Y, Qiao W, Yuanxin C, Ren Y, Kurti A, Shue F, Parsons TM, Perkerson RB, Kawatani K, Wang N, Starling SC, Roy B, Mosneag IE, Aikawa T, Holm ML, Liu CC, Inoue Y, Sullivan PM, Asmann YW, Kim BYS, Bu G, Kanekiyo T. LRP1 in vascular mural cells modulates cerebrovascular integrity and function in the presence of APOE4. JCI Insight 8(7), 2023. e-Pub 2023. PMID: 37036005.
Lu Y, Huntoon K, Lee D, Wang Y, Ha J, Qie Y, Li X, Schrank BR, Dong S, Gallup TD, Kang M, Zhao H, An Y, Yang Z, Li J, Kim BYS, Jiang W. Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy. Nature Nanotechnology 17(12):1332-1341, 2022. e-Pub 2022. PMID: 36357792.
Li X, Khorsandi S, Wang Y, Santelli J, Huntoon K, Nguyen N, Yang M, Lee D, Lu Y, Kim BYS, Lux C, Mattrey RF, Jiang W, Lux J. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Nature Nanotechnology 17(8):891-899, 2022. e-Pub 2022. PMID: 35637356.
Liu CC, Wang N, Chen Y, Inoue Y, Shue F, Linares C, Kurti A, Fryer JD, Zhang B, Kim BYS, Bu G. Peripheral apoE4 enhances Alzheimer’s pathology and impairs cognition by compromising cerebrovascular function. Nature Neuroscience 25(8):1020-1033, 2022. e-Pub 2022. PMID: 35915180.
Hsieh RCE, Krishnan S, Wu RC, Boda AR, Liu A, Winkler M, Lea ST, Taniguchi C, Kim BYS, Chen J, Rudqvisst NP, Curran M. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Science Immunology 7(72), 2022. e-Pub 2022. PMID: 35687697.
Abdelfattah N, Kumar P, J-S L, Flynn W, Gao R, Baskin D, Pichumani K, Ijare O, Wood S, Powell S, Haviland D, Kim BYS, Jiang W, George J, Yun K. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nature Communications 13(1):967, 2022. e-Pub 2022. PMID: 35140215.
Yang, Z, Shi, J, Xie, J, Wang, Y, Sun, J, Liu, T, Zhao, Y, Zhao, X, Wang, X, Ma, Y, Malkoc, V, Chiang, C, Deng, W, Chen, Y, Fu, Y, Kwak, KJ, Fan, Y, Kang, C, Yin, C, Rhee, J, Bertani, P, Otero, J, Lu, W, Yun, K, Lee, AS, Jiang, W, Teng, L, Kim, BY, Lee, LJ. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nature Biomedical Engineering 5(8):944-945, 2021. e-Pub 2021. PMID: 34131325.
Lee D, Huntoon K, Wang Y, Jiang W, Kim BYS. Harnessing innate immunity using biomaterials for cancer immunotherapy. Advanced Materials 33(27), 2021. e-Pub 2021. PMID: 34050699.
Yamazaki Y, C-C L, Yamazaki A, Shue F, Martens YA, Chen Y, Qiao W, Kurti A, Que H, Ren Y, Li Y, Aikawa T, Cherukuri Y, Fryer JD, Asmann YW, Kim BYS, Kanekiyo T, Bu G. Vascular ApoE4 Impairs Behavior by Modulating Gliovascular Function. Neuron 109(3):438-447.e6, 2021. e-Pub 2021. PMID: 33321072.
Jiang W, Wang Y, Wargo JA, Lang FF, Kim BYS. Considerations for designing preclinical cancer immune nanomedicine studies. Nature Nanotechnology 16(1):6-15, 2021. e-Pub 2021. PMID: 33349682.
Deng W, Wang Y, Liu X, Liu J, Wang L, Yang Z, Yang M, An Y, Tang C, Sanford N, Kim BYS, Jiang W. Assessment of Trends in Second Primary Cancers in Patients with Metastatic Melanoma from 2005 to 2016. JAMA Network Open 3(12), 2020. e-Pub 2020. PMID: 33295975.
von Roemeling CA, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, Yang Z, Yang M, Deng W, Bruno KA, Chan CK, Lee AS, Rosenfeld SS, Yun K, Johnson AJ, Mitchell DA, Jiang W, Kim BYS. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nature Communications 11(1), 2020. e-Pub 2020. PMID: 32198351.
Yang Z, Shi J, Xie J, Wang Y, Sun J, Liu T, Zhao Y, Zhao X, Wang X, Ma Y, Malkoc V, Chiang C, Deng W, Chen Y, Fu Y, Kwak KJ, Fan Y, Kang C, Yin C, Rhee J, Bertani P, Otero J, Lu W, Yun K, Lee AS, Jiang W, Teng L, Kim BYS, Lee LJ. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nature Biomedical Engineering 4(1):69-83, 2020. e-Pub 2020. PMID: 31844155.
Leong HS, Butler KS, Brinker CJ, Azzawi M, Conlan S, Dufès C, Owen A, Rannard S, Scott C, Chen C, Dobrovolskaia MA, Kozlov SV, Prina-Mello A, Schmid R, Wick P, Caputo F, Boisseau P, Crist RM, McNeil SE, Fadeel B, Tran L, Hansen SF, Hartmann NB, Clausen LPW, skjolding LM, Baun A, Ågerstrand M, Gu Z, Lamprou DA, Hoskins C, Huang L, Song W, Cao H, Liu X, Jandt KD, Jiang W, Kim BYS, Wheeler KE, Chetwynd AJ, Lynch I, Moghimi SM, Nel A, Xia T, Weiss PS, Sarmento B, das Neves J, Santos HA, Santos L, Mitragotri S, Little S, Peer D, Amiji MM, Alonso MJ, Petri-Fink A, Balog S, Lee A, Drasler B, Rothen-Rutishauser B, Wilhelm S, Acar H, Harrison RG, Mao C, Mukherjee P, Ramesh R, McNally LR, Busatto S, Wolfram J, Bergese P, Ferrari M, Fang RH, Zhang L, Zheng J, Peng C, Du B, Yu M, Charron DM, Zheng G, Pastore C. On the issue of transparency and reproducibility in nanomedicine. Nature Nanotechnology 14(7):629-635, 2019. e-Pub 2019. PMID: 31270452.
Liu Z, Jiang W, Nam J, Moon JJ, Kim BYS. Immunomodulating Nanomedicine for Cancer Therapy. Nano Letters 18(11):6655-6659, 2018. e-Pub 2018. PMID: 30185039.
Ioannidis JPA, Kim BYS, Trounson A. How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. Nature Biomedical Engineering 2(11):797-809, 2018. e-Pub 2018. PMID: 30931172.
Yuan H, Jiang W, von Roemeling CA, Qie Y, Liu X, Chen Y, Wang Y, Wharen RE, Yun K, Bu G, Knutson KL, Kim BYS. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nature Nanotechnology 12(8):763-769, 2017. e-Pub 2017. PMID: 28459470.
Jiang, W, Von Roemeling, CA, Chen, Y, Qie, Y, Liu, X, Chen, J, Kim, BYS. Designing nanomedicine for immuno-oncology. Nature Biomedical Engineering 1(2):0029, 2017. e-Pub 2017.
Jiang W, Huang Y, An Y, Kim BYS. Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. ACS Nano 9(9):8689-8696, 2015. e-Pub 2015. PMID: 26212564.
Kim BYS, Rutka JT, Chan WC. Nanomedicine. New England Journal of Medicine 363(25):2434-2443, 2010. e-Pub 2010. PMID: 21158659.
Kim BYS, Jiang W, Oreopoulos J, Yip CM, Rutka JT, Chan WC. Biodegradable quantum dot nanocomposites enable live cell labeling and imaging of cytoplasmic targets. Nano Letters 8(11):3887-3892, 2008. e-Pub 2008. PMID: 18816147.
Jiang W, Kim BYS, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent. Nature Nanotechnology 3(3):145-150, 2008. e-Pub 2008. PMID: 18654486.
Zhu S, Stavrovskaya IG, Drozda M, Kim BYS, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417(6884):74-78, 2002. e-Pub 2002. PMID: 11986668.
Abounader R, Ranganathan S, Kim BYS, Nichols C, Laterra J. Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. Journal of Neurochemistry 76(5):1497-1508, 2001. e-Pub 2001. PMID: 11238734.

Invited Articles

Huntoon K, Lee DY, Dong S, Antony A, Kim BYS, Jiang W. Targeting phagocytosis to enhance antitumor immunity. Trends Cancer (Cell Press), 2023. e-Pub 2023. PMID: 37150626.

Review Articles

Jeong SD, Schrank BR, Mancuso JJ, Kim BYS, Jiang W, Sharma P. Translational Challenges and Opportunities in mRNA Cancer Vaccines. Cancer Discov 16(9):1739-1749, 2026. e-Pub 2026. PMID: 42676099.
Wu A, Jeong SD, Schrank BR, Kim BYS, Sharma P, Jiang W. Programming the immunological properties of mRNA vaccines for cancer. Nat Rev Immunol, 2026. e-Pub 2026. PMID: 42321479.
Argenziano MG, Neelakantan TV, Sperring C, Adeuyan O, Higgins DMO, Bruce JN, Kim BYS, Dovas A, Canoll P, Lim M, Stockwell BR, Banu MA. Emerging roles of ferroptosis in modulating the immune landscape of glial tumours. Nat Cell Biol 28(7):1364-1378, 2026. e-Pub 2026. PMID: 42225830.
Ma Y, Dong S, Wu A, Jeong SD, Lee AS, Jiang W, Kim BYS. Engineering challenges and translational opportunities in emerging gene delivery platforms. Nat Biomed Eng 10(6):1060-1083, 2026. e-Pub 2026. PMID: 42092003.
Zhang H, Grippin A, Sun M, Ma Y, Kim BYS, Teng L, Jiang W, Yang Z. New avenues for cancer immunotherapy: Cell-mediated drug delivery systems. J Control Release 375:712-732, 2024. e-Pub 2024. PMID: 39326499.
Ma Y, Dong S, Grippin AJ, Teng L, Lee AS, Kim BYS, Jiang W. Engineering therapeutical extracellular vesicles for clinical translation. Trends Biotechnol, 2024. e-Pub 2024. PMID: 39227240.
Lee DY, Huntoon K, Lux J, Kim, BYS, Jiang W. Engineering nanomaterial physical characteristics for cancer immunotherapy. Nature Reviews Bioengineering 1:499-517, 2023. e-Pub 2023.
Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nature Reviews Cancer 19(10):568-586, 2019. e-Pub 2019. PMID: 31462760.
Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nature Reviews Immunology 18(3):195-203, 2018. e-Pub 2018. PMID: 29332937.
Jiang W, Yuan H, Chan CK, von Roemeling CA, Yan Z, Weissman IL, Kim BYS. Lessons from Immuno-Oncology: A New Era for Cancer Nanomedicine. Nature Reviews Drug Discovery 16(6):369-370, 2017. e-Pub 2017. PMID: 28303024.
von Roemeling C, Jiang W, Chan CK, Weissman IL, Kim BYS. Breaking Down the Barriers to Precision Cancer Nanomedicine. Trends in Biotechnology (Cell Press) 35(2):159-171, 2017. e-Pub 2017. PMID: 27492049.
Jiang W, Chan CK, Weissman IL, Kim, BYS, Hahn SM. Immune Priming of the Tumor Microenvironment by Radiation. Trends in Cancer (Cell Press) 2(11):638-645, 2016. e-Pub 2016. PMID: 28741502.
Rutka JT, Kim BYS, Etame A, Diaz RJ. Nanosurgical resection of malignant brain tumors: Beyond the cutting edge. ACS Nano 8(10):9716-9722, 2014. e-Pub 2014. PMID: 25233362.

Editorials

Ha JH, Grippin A, Kim BYS, Jiang W. Striking the Balance with PD-L1x4-1BB Bispecific Antibody. Cancer Research 84(10):1546-1547, 2024. PMID: 38745496.
Huntoon K, Jiang W, Kim BYS. Waking immune-resistant tumors with neddylation. Journal of Clinical Investigation 133(4), 2023. PMID: 36787255.

Abstracts

Jiang W, Chen Y, Lin SH, Kim BYS. In vivo imaging and quantification of oxygen tension within solid tumor. Journal of Clinical Oncology, 2016. e-Pub 2016.
Jiang W, Chamberlain PD, Garden AS, Kim BYS, Ma D, Bell D. Prognostic value of p16 expression in Epstein‐Barr virus–positive nasopharyngeal carcinomas. Head & Neck, 2016. e-Pub 2016.
Chen Y, Jiang W, Qie Y, Liu X, von Roemeling C, Shih K, Wharen RE, Kim BYS. Priming of the brain tumor microenvironment enables improved nanomedicine delivery. Neurosurgery, 2016. e-Pub 2016.
Kim BYS, Jiang W, Beiko J, Prabhu P, Demonte F, Lang F, Gilbert M. IDH1 status as a diagnostic and prognostic marker for malignant astrocytomas with limited histological specimen: The role of surgical resection. Neuro-Oncology, 2013. e-Pub 2013.

Book Chapters

Ha, JH, Jiang, W, Huntoon, K, Lee, DY, Kim, YB. Cancer nanomedicines for enhanced immunotherapy, V3-657-V3-672, 2023.
Lee, DY, Huntoon, K, Kim, BYS, Jiang, W. Challenges and opportunities of nanotechnology in cancer immunotherapy, 197-239, 2022.
Ha JH, Huntoon K, Lee D, Kim BYS, Jiang W. Cancer nanomedicines for enhanced immunotherapy. In: Materials Science and Materials Engineering, 2022.
Yang, Z, Ma, Y, Zhao, H, Yuan, Y, Kim, BYS. Nanotechnology platforms for cancer immunotherapy. In: Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020.
Gassie K, Bradley B, Wharen RE, Kim BYS, Rabinstein AA, Freeman WD. Management of the Neurosurgical Craniotomy Patient. In: Neuro Critical Care. Oxford University Press 3 rd ed, 2019.
Yoon JW, Jiang W, Rutka JT, Huang Y, Kim BYS. Perspectives of Nanotechnology in the Management of Gliomas. In: Progress of Neurological Surgery. Karger, Berlin, 196-210, 2018.

Books (edited and written)

Kim BYS, Citow JS, Macdonald RL, Refai D. Comprehensive Neurosurgery Board Review. Thieme, 2010.

Letters to the Editor

Jiang W, Liu J, Gullane PJ, Gentili F, Wharen RE, Kim BYS, DeMonte F. Non-contiguous meningeal metastases of olfactory neuroblastoma. Journal of Neuro-Oncology 126: 201-203, 2016.

Patents

Kim BYS. Methods and Compositions for Production of MRNA-Loaded Exosomes for Targeted Immunotherapy. Patent Number: PCT/US2024/049284.
Kim BYS, Jiang W, Lee DY, Huntoon K. Polypeptide Adjuvants and Uses Thereof. Patent Number: (MDA21-130).
Copland III JA, Von Roemeling C, Tun HW, Caulfield TR, Kim BYS. Compounds and Methods for Treating Cancer. Patent Number: US Patent Application 18/101,772.
Kim BYS, Jiang W, Von Roemeling C. Methods and Materials for Treating Cancer. Patent Number: US Patent 11,555,056 (MDA18-095).
Kim BYS, Jiang W. Methods and Material for Treating Cancer. Patent Number: US Patent Application 18/082,960 (MDA18-095).
Kim BYS, Wharen RE, Yuan H, Jiang W. Methods and Materials for Treating Cancer. Patent Number: US10,556,965.
Kim BYS, Jiang W. Methods and Materials for Treating Cancer. Patent Number: US Patent Application 17/263,689 (MDA24-026).
Copland III JA, Von Roemeling C, Tun HW, Caulfield TR, Kim BYS. Compounds and Methods for Treating Cancer. Patent Number: US11,596,629.
Jiang W, Schrank BR, Wang Y, Kim BYS. Methods and Compositions for Treating Cancer. Patent Number: US Provisional Application, unpublished (MDA21-087).
Kim BYS, Jiang W, Lu Y, Huntoon K. An Adjuvant and CD47-Blockade Combination Cancer Treatment and Methods of Using the Same. Patent Number: US Patent Application PCT/US2023/078492 (MDA22-041).
Kim BYS, Jiang W, Dong S, Yang Z, Wang S. A Method to Engineer and Produce Extracellular Vesicles. Patent Number: US Provisional Application, Unpublished (MDA23-002).
Jiang W, Wang Y, Kim BYS. Compositions and Methods for MARCO Inhibition and Improved Drug Delivery. Patent Number: US Patent Application PCT/US2023/075419 (MDA22-050).
Kim BYS, Wharen RE, Yuan H, Jiang W. Methods and Materials for Treating Cancer. Patent Number: US Patent 11,034,773.